Compare ClearPoint Neuro Inc (CLPT) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Invesco Ltd. — how do they compare? ClearPoint Neuro Inc trades at $15.22 (market cap $454.21M), while Invesco Ltd. trades at $31.63 (market cap $13.85B). The key difference: Invesco Ltd. is far larger — about 30.5× ClearPoint Neuro Inc's market cap, and Invesco Ltd. pays a 2.74% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | IVZ | |
|---|---|---|
Market Cap | $454.21M | $13.85B |
Sector | Health | Financials |
52-Week High | $29.60 | $32.01 |
52-Week Low | $8.66 | $20.67 |
Enterprise Value | $488.79M | $24.01B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Invesco (IVZ) trades at $31.52, down 0.69% today, near its consensus price target of $32.50. The stock shows a bullish technical signal with moving averages supporting an uptrend, while recent earnings have been mixed with Q2 2026 beating expectations. Revenue grew to $6.38 billion in 2025, though net income was negative. Analyst sentiment is balanced with 12 buy and 16 hold ratings, and the company maintains a stable dividend.
The outlook for IVZ hinges on sustained asset under management growth and expense control to return to profitability. Key risks include market volatility affecting AUM and competitive pressures. Upside potential exists if operational improvements continue, but investors face uncertainty from inconsistent earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
